Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novavax Inc (NVAX) vs Ferrari NV (RACE) Price & Performance

Novavax IncTrade
Ferrari NVTrade

Price performance (Past 24H)

Key statistics

Novavax Inc vs Ferrari NV — how do they compare? Novavax Inc trades at $7.89 (market cap $1.31B), while Ferrari NV trades at $406.38 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 54.7× Novavax Inc's market cap, and Ferrari NV pays a 1.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

NVAXRACE
Market Cap
$1.31B$71.67B
Sector
HealthConsumer Cyclical
52-Week High
$11.19$504.09
52-Week Low
$6.22$314.63
Enterprise Value
$889.30M$73.60B
Dividend Yield
1.04%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novavax Inc

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.

Ferrari NV

Ferrari (RACE) trades at $407.76, up 0.24% today, near its pivot point of $407 with bullish technical indicators. The stock shows strong fundamentals with a 22.25% net margin and consistent earnings beats, including Q2 2026 EPS of $2.99 versus $2.83 expected. Revenue growth is steady, reaching $7.15B in 2025, supported by high demand and personalization revenue.

Outlook remains positive with a consensus price target of $462.67, though elevated P/E of 37.93 poses valuation risk. Key opportunities include pricing power and EV expansion, while risks involve economic sensitivity and execution on new models. Analyst sentiment is strongly bullish with 72% buy ratings.

Returns comparison

Trailing returns across standard periods

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX

About Ferrari NV

Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.

Read more on RACE